| 1 |
33746969 | Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. | 2021 |
1 |
| 2 |
33925565 | LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. | 2021 Apr 27 |
1 |
| 3 |
25398834 | Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. | 2015 Feb |
1 |
| 4 |
24292625 | Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. | 2014 Jan 17 |
1 |
| 5 |
25313353 | Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. | 2014 |
1 |
| 6 |
25610725 | Lenalidomide induces degradation of IKZF1 and IKZF3. | 2014 |
2 |
| 7 |
22774993 | Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients. | 2012 Aug |
1 |
| 8 |
20978269 | The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. | 2011 Feb 3 |
2 |
| 9 |
21130040 | Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. | 2011 Feb |
3 |
| 10 |
20088798 | Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. | 2010 Mar |
1 |
| 11 |
19728370 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. | 2009 Nov 15 |
1 |
| 12 |
17724360 | Lenalidomide in the treatment of multiple myeloma. | 2007 Sep 1 |
1 |
| 13 |
16357183 | Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. | 2005 Dec 15 |
1 |